3,185 Shares in Boston Scientific Co. (NYSE:BSX) Acquired by Accel Wealth Management

Accel Wealth Management bought a new stake in shares of Boston Scientific Co. (NYSE:BSX) during the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund bought 3,185 shares of the medical equipment provider’s stock, valued at approximately $218,000.

Several other institutional investors have also recently made changes to their positions in the stock. Bruce G. Allen Investments LLC purchased a new stake in Boston Scientific during the 4th quarter worth about $28,000. Northwest Investment Counselors LLC bought a new stake in shares of Boston Scientific during the first quarter valued at about $31,000. Sachetta LLC purchased a new stake in shares of Boston Scientific in the fourth quarter worth about $32,000. Frazier Financial Advisors LLC bought a new position in shares of Boston Scientific in the fourth quarter valued at approximately $32,000. Finally, Jones Financial Companies Lllp grew its stake in Boston Scientific by 53.0% during the fourth quarter. Jones Financial Companies Lllp now owns 557 shares of the medical equipment provider’s stock valued at $32,000 after acquiring an additional 193 shares in the last quarter. Hedge funds and other institutional investors own 89.07% of the company’s stock.

Analysts Set New Price Targets

Several research analysts have commented on BSX shares. Deutsche Bank Aktiengesellschaft raised their price target on shares of Boston Scientific from $63.00 to $73.00 and gave the company a “hold” rating in a report on Thursday, April 25th. Barclays boosted their target price on Boston Scientific from $70.00 to $78.00 and gave the stock an “overweight” rating in a research report on Friday, April 26th. Robert W. Baird lifted their price target on Boston Scientific from $79.00 to $84.00 and gave the company an “outperform” rating in a research report on Thursday, April 25th. Raymond James upped their price objective on shares of Boston Scientific from $73.00 to $85.00 and gave the stock a “strong-buy” rating in a research report on Thursday, April 25th. Finally, Needham & Company LLC reaffirmed a “buy” rating and set a $82.00 price objective on shares of Boston Scientific in a report on Tuesday, June 18th. Three research analysts have rated the stock with a hold rating, eighteen have issued a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $77.41.

Insider Buying and Selling at Boston Scientific

In related news, Director Edward J. Ludwig sold 9,818 shares of Boston Scientific stock in a transaction on Friday, April 26th. The stock was sold at an average price of $73.29, for a total value of $719,561.22. Following the completion of the sale, the director now owns 41,374 shares of the company’s stock, valued at $3,032,300.46. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. In other news, Director Edward J. Ludwig sold 9,818 shares of the business’s stock in a transaction on Friday, April 26th. The shares were sold at an average price of $73.29, for a total transaction of $719,561.22. Following the completion of the sale, the director now owns 41,374 shares of the company’s stock, valued at approximately $3,032,300.46. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, EVP John Bradley Sorenson sold 17,587 shares of the business’s stock in a transaction dated Wednesday, May 1st. The shares were sold at an average price of $71.50, for a total value of $1,257,470.50. Following the sale, the executive vice president now directly owns 50,638 shares of the company’s stock, valued at approximately $3,620,617. The disclosure for this sale can be found here. In the last ninety days, insiders sold 72,259 shares of company stock worth $5,344,014. Insiders own 0.50% of the company’s stock.

Boston Scientific Stock Down 0.6 %

Boston Scientific stock opened at $76.11 on Friday. Boston Scientific Co. has a 12 month low of $48.35 and a 12 month high of $77.99. The stock has a fifty day simple moving average of $75.28 and a two-hundred day simple moving average of $68.07. The firm has a market cap of $111.66 billion, a price-to-earnings ratio of 63.96, a PEG ratio of 2.62 and a beta of 0.78. The company has a current ratio of 1.66, a quick ratio of 1.14 and a debt-to-equity ratio of 0.47.

Boston Scientific (NYSE:BSX) last announced its quarterly earnings results on Wednesday, April 24th. The medical equipment provider reported $0.56 EPS for the quarter, topping analysts’ consensus estimates of $0.51 by $0.05. The firm had revenue of $3.86 billion during the quarter, compared to analyst estimates of $3.68 billion. Boston Scientific had a net margin of 12.06% and a return on equity of 16.39%. Equities analysts predict that Boston Scientific Co. will post 2.32 EPS for the current fiscal year.

Boston Scientific Company Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.